What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Raul R. Trejo-Rosales, MD
Advertisement
Articles by Raul R. Trejo-Rosales, MD
Advertisement
Latest Updated Articles
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?Published: August 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
